Most side effects are common and they eventually go away on their own (or after receiving medication)
Osteoboost offers hope to millions with low bone density, helping reduce fracture risk that threatens mobility and independence
Thereby, it can be, in general, a vascular recovery depending on the given injury [40,41,42,43,47,48,49,50,51,52,53,54,55,56]
Thus, these results suggest that GLP-1RAs exhibit superior preventive effects on atherosclerotic CV events and can improve CV prognosis in T2D patients with a previous history of CV events (except ACS), and that such treatment effects could become apparent by, for example, comparing the results of CV outcomes trials with another class of incretin-based agents, namely dipeptidyl peptidase-4 (DPP-4) inhibitors [31,32,33]